MA45987A - Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation - Google Patents

Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation

Info

Publication number
MA45987A
MA45987A MA045987A MA45987A MA45987A MA 45987 A MA45987 A MA 45987A MA 045987 A MA045987 A MA 045987A MA 45987 A MA45987 A MA 45987A MA 45987 A MA45987 A MA 45987A
Authority
MA
Morocco
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
MA045987A
Other languages
English (en)
French (fr)
Inventor
Michelle Kasem
Albert S Ren
Thomas O Schrader
Graeme Semple
Xiuwen Zhu
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA45987A publication Critical patent/MA45987A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045987A 2016-08-19 2017-08-18 Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation MA45987A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662377119P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
MA45987A true MA45987A (fr) 2019-06-26

Family

ID=59799461

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045987A MA45987A (fr) 2016-08-19 2017-08-18 Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation

Country Status (14)

Country Link
US (2) US10836764B2 (enExample)
EP (1) EP3500570B1 (enExample)
JP (1) JP6977024B2 (enExample)
KR (1) KR20190049732A (enExample)
CN (1) CN109952301B (enExample)
AU (1) AU2017313908C1 (enExample)
BR (1) BR112019003142A2 (enExample)
CA (1) CA3033142A1 (enExample)
EA (1) EA038219B1 (enExample)
IL (1) IL264682B (enExample)
MA (1) MA45987A (enExample)
MX (1) MX391442B (enExample)
NZ (1) NZ750469A (enExample)
WO (1) WO2018035477A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500570B1 (en) * 2016-08-19 2022-10-05 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
EP3860996A4 (en) 2018-10-02 2022-08-31 Northwestern University BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C)
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US20230277568A1 (en) * 2020-07-10 2023-09-07 Eleusis Therapeutics Us, Inc. Method of treatment for psilocybin or psilocin infusion
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
AU8057491A (en) 1990-07-03 1992-02-04 Quaker Chemical Corporation (A Delaware Corporation) Aqueous coolant
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
EP1494533A2 (en) 2002-04-12 2005-01-12 The University of Chicago Farnesoid x-activated receptor agonists
JP5520051B2 (ja) * 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JP6272695B2 (ja) * 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015161285A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
EP3500570B1 (en) * 2016-08-19 2022-10-05 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
CA3033142A1 (en) 2018-02-22
EA038219B1 (ru) 2021-07-26
US10836764B2 (en) 2020-11-17
JP2019524844A (ja) 2019-09-05
EP3500570A1 (en) 2019-06-26
MX391442B (es) 2025-03-21
NZ750469A (en) 2023-03-31
AU2017313908A1 (en) 2019-02-28
US20190225612A1 (en) 2019-07-25
US20210214355A1 (en) 2021-07-15
IL264682B (en) 2021-08-31
CN109952301B (zh) 2022-03-25
CN109952301A (zh) 2019-06-28
US11608339B2 (en) 2023-03-21
WO2018035477A1 (en) 2018-02-22
EP3500570B1 (en) 2022-10-05
MX2019002020A (es) 2019-11-25
KR20190049732A (ko) 2019-05-09
AU2017313908B2 (en) 2021-10-21
JP6977024B2 (ja) 2021-12-08
AU2017313908C1 (en) 2022-06-09
BR112019003142A2 (pt) 2019-05-21
EA201990527A1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
EP3429591A4 (en) SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE
EP3402549A4 (en) MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF
EP3684361A4 (en) SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
EP3600325A4 (en) UNIQUE COMPOSITIONS AND PROCESSES
EP3373969A4 (en) GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
EP3313404A4 (en) THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE
IL255171A0 (en) 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use
EP3316894A4 (en) COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3352774A4 (en) FLAVONOID COMPOSITIONS AND METHODS OF USE
EP3353309A4 (en) COMPOSITIONS AND METHOD FOR GENERIC EDITING
EP3317273A4 (en) EGFR HEMMER AND METHOD OF USE THEREOF
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP2971065A4 (en) ACTIVITY-BASED PROBE CONNECTIONS, COMPOSITIONS AND METHODS OF USE
EP3364984A4 (en) COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA44087A (fr) Immunothérapie basée sur la listéria et ses méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
EP3510380A4 (en) Activity-based probe compounds, compositions, and methods of use